Daniel A. Laheru
Advanced in Large-Cell Lung Carcinoma

Dr. Daniel A. Laheru

Oncology
Johns Hopkins University
600 N Wolf St, 
Baltimore, MD 
Accepting New Patients
Offers Telehealth
Advanced in Large-Cell Lung Carcinoma
Johns Hopkins University
600 N Wolf St, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel Laheru is an Oncologist in Baltimore, Maryland. Dr. Laheru is rated as an Advanced provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Laheru is currently accepting new patients.

His clinical research consists of co-authoring 166 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
Sibley Memorial Hospital
The Johns Hopkins Hospital
Johns Hopkins Howard County Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

JOHNS HOPKINS UNIVERSITY
600 N Wolf St, Baltimore, MD 21287

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: FOLFIRINOX, Losartan, Nivolumab
Study Phase: Phase 2
Phase II Study to Evaluate Stereotactic Body Radiation Therapy For Palliative Management of Unresectable Recurrent or Residual Pancreatic or Periampullary Adenocarcinoma
Phase II Study to Evaluate Stereotactic Body Radiation Therapy For Palliative Management of Unresectable Recurrent or Residual Pancreatic or Periampullary Adenocarcinoma
Enrollment Status: Completed
Publish Date: July 20, 2025
Intervention Type: Radiation
Study Phase: Phase 2
A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Enrollment Status: Terminated
Publish Date: May 28, 2025
Intervention Type: Biological, Drug
Study Drugs: NIS793, Spartalizumab, Gemcitabine, Nab-paclitaxel
Study Phase: Phase 2
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drugs: Gemcitabine, Nab-paclitaxel, SM-88, mFOLFIRINOX
Study Phase: Phase 3
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drugs: Cabozantinib, Nivolumab
Study Phase: Phase 1
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Enrollment Status: Terminated
Publish Date: July 17, 2024
Intervention Type: Drug, Biological, Procedure
Study Drugs: Poly-ICLC, CD4/CD8-Positive Personalized Neoantigen Peptide Vaccine
Study Phase: Phase 1
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen DNA Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen DNA Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Enrollment Status: Terminated
Publish Date: October 10, 2023
Intervention Type: Biological, Procedure, Device
Study Drug: Personalized Neoantigen DNA Vaccine
Study Phase: Phase 1
A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 DART® Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma
A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 DART® Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Prospective, Multinational, Multi-Center, Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of siG12D-LODER in Combination With Standard of Care Chemotherapy in the Treatment of Patients With Locally Advanced Pancreatic Cancer
A Prospective, Multinational, Multi-Center, Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of siG12D-LODER in Combination With Standard of Care Chemotherapy in the Treatment of Patients With Locally Advanced Pancreatic Cancer
Enrollment Status: Unknown
Publish Date: July 02, 2021
Intervention Type: Drug
Study Drugs: siG12D-LODER, Gemcitabine+Nab-Paclitaxel, Folfirinox
Study Phase: Phase 2
View 8 Less Clinical Trials

166 Total Publications

Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.
Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 24, 2025
Similar Doctors
Julie R. Brahmer
Distinguished in Large-Cell Lung Carcinoma
Dr. Julie R. Brahmer
Oncology
Distinguished in Large-Cell Lung Carcinoma
Dr. Julie R. Brahmer
Oncology

Johns Hopkins University

301 Mason Lord Dr, Suite 1201, 
Baltimore, MD 
 (2.5 miles away)
410-550-2339
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Julie Brahmer is an Oncologist in Baltimore, Maryland. Dr. Brahmer is rated as an Elite provider by MediFind in the treatment of Large-Cell Lung Carcinoma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Brahmer is currently accepting new patients.

Janakiraman Subramanian
Distinguished in Large-Cell Lung Carcinoma
Dr. Janakiraman Subramanian
Oncology | Hematology
Distinguished in Large-Cell Lung Carcinoma
Dr. Janakiraman Subramanian
Oncology | Hematology

Inova Health Care Services

3600 Joseph Siewick Dr, 
Fairfax, VA 
 (51.0 miles away)
703-391-3600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Janakiraman Subramanian is an Oncologist and a Hematologist in Fairfax, Virginia. Dr. Subramanian is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Bone Marrow Aspiration, and Tissue Biopsy. Dr. Subramanian is currently accepting new patients.

Distinguished in Large-Cell Lung Carcinoma
Dr. Josephine L. Feliciano
Hematology Oncology | Hematology | Oncology
Distinguished in Large-Cell Lung Carcinoma
Dr. Josephine L. Feliciano
Hematology Oncology | Hematology | Oncology

Johns Hopkins University

4940 Eastern Ave, 
Baltimore, MD 
 (2.5 miles away)
410-550-0100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Josephine Feliciano is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Feliciano is rated as an Elite provider by MediFind in the treatment of Large-Cell Lung Carcinoma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Feliciano is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Laheru's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 18 Advanced Conditions
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile